Clinical Trial Update: A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations [Phase 4]

View source ↗

Summary

Phase 4 study results reported for erlotinib (Tarceva) as first-line therapy in patients with locally advanced or metastatic EGFR-mutant non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Squamous Non-Small Cell Lung Cancer | Phase 4 | Status: COMPLETED | Results posted: 2016-02-01